Larken Labs

Larken Labs is a clinical-stage specialty pharmaceutical company focused on the development of novel treatments for dermatological and inflammatory conditions. The company's strategy involves enhancing the delivery and efficacy of established therapeutic agents through proprietary topical formulations. Its lead program, LKN-001, is currently in clinical development for the treatment of seborrheic dermatitis, a common inflammatory skin condition. Larken Labs aims to address unmet needs in dermatology by providing patients with more effective and better-tolerated therapeutic options. The company utilizes a lean, capital-efficient model to advance its candidates through the clinical trial process.